Post-SSRI Sexual Dysfunction (PSSD)
Persistent Sexual Dysfunction After Stopping Antidepressants
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- EMA acknowledged label warning (2019); no approved treatment
Reference only. Not medical advice.
What can go wrong
The condition itself is the harm: distressing, potentially long-lasting genital numbness, loss of libido, and orgasmic/erectile dysfunction with emotional blunting, sometimes with major quality-of-life and mental-health impact. Because evidence is limited, patients are vulnerable to unproven and costly 'cures.' This must be balanced against the real benefits and risks of stopping needed antidepressant therapy, which should never be discontinued without medical guidance.
This is something to take to a clinician. The Atlas can tell you what is known about post-ssri sexual dysfunction (pssd) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Post-SSRI sexual dysfunction (PSSD) is a syndrome of persistent sexual and emotional symptoms that continue after discontinuing SSRI or SNRI antidepressants. Core features are genital numbness, loss of libido, and difficulty with orgasm or erection, often with emotional blunting and anhedonia. In June 2019 the European Medicines Agency acknowledged that sexual dysfunction may persist after stopping these drugs and required label updates. Prevalence is unknown, mechanisms are unproven, and there is no established treatment.
Sexual side effects that persist long after the antidepressant is stopped.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Mechanisms are hypothesized but unproven. Proposed contributors include lasting changes in serotonergic/dopaminergic signaling, downregulation of genital sensory pathways, epigenetic changes, and altered neurosteroid or hormonal signaling. The defining and puzzling feature is symptom persistence after the drug and its metabolites have cleared.
What people get wrong
Often saidPSSD is just ongoing depression
ActuallyPatients report symptoms persisting after mood recovery and drug clearance, and emotional blunting/genital numbness differ from typical depressive low libido.
Often saidPSSD is proven and common with a known cure
ActuallyPrevalence is unquantified, mechanisms are unproven, and no treatment is established; the EMA acknowledgment reflects recognition, not full characterization.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- EMA action
- 2019 label warning that dysfunction can persist after stopping
- Core symptoms
- Genital numbness, low libido, anorgasmia/ED
- Associated features
- Emotional blunting, anhedonia
- Approved treatment
- None established
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Post-SSRI Sexual Dysfunction (PSSD). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
EMA PRAC review and label change2019
European regulator acknowledged sexual dysfunction may persist after SSRI/SNRI discontinuation; required product information updates
PSSD case series and proposed diagnostic criteria2021
Reviews characterized symptoms, biological plausibility, and barriers to estimating incidence